Skip to Main content Skip to Navigation
New interface
Journal articles

Grams ME, Sang Y, Ballew SH, et al, for the Chronic Kidney Disease Prognosis Consortium. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93:1442–1451

Philippe Remy 1 Vincent Audard 1 Pierre André Natella 2 Gaëlle Pelle 3 Bertrand Dussol 4, 5 Hélène Leray-Moragues 6 Khedidja Bouachi 7 Jacques Dantal 8 Laurence Vrigneaud 9 Alexandre Karras 10 Frank Pourcine 1 Philippe Gatault 11 Philippe Grimbert 1 Nawelle Ait Sahlia 1 Anissa Moktefi 12 Eric Daugas 13 Claire Rigothier 14 Sylvie Bastuji-Garin 15 Dil Sahali 16 Jean Claude Aldigier Pierre Bataille 17 Bernard Canaud 6 Dominique Chauveau 18 Christian Combe 19 Gabriel Choukroun 20 Emilie Cornec-Legall 21 Karine Dahan 22 Michel Delahousse 23 Dominique Desvaux 24 Patrice Deteix 25 Antoine Durrbach 26 Vincent Esnault 27 Marie Essig 28 Patrick Fievet 29 Thierry Frouget 30 Dominique Guerrot 31 Michel Godin 32 Annie Gontiers-Picard Morgane Gosselin Catherine Hanrotel-Saliou 33 Anne-Elisabeth Heng 34 Antoine Huart 18 Antoine Humbert Tomek Kofman 24 Aurélie Hummel 35 Philippe Lang 24 Maurice Laville 36 Yannick Lemeur 21 Paolo Malvezzi 37 Marie Matignon 24 Rafik Mesbah 38 Bruno Moulin 39 Sandrine Muller Jerome Olagne Agathe Pardon 7 François Provôt 40 Guillaume Queffeulou 41 Emmanuelle Plaisier 42 Quentin Raimbourg 43 Philippe Rieu 44 Thomas Stehlé 45 Philippe Vanhille 46 Brad Astor Adeera Levin 47 Mila Tang Ognjenka Djurdjev Sankar Navaneethan Stacey Jolly Jesse Schold Joseph Nally Jonathan Emberson John Townend 48 Martin Landray Harold Feldman Chi-Yuan Hsu James Lash Lawrence Appel Philip Kalra James Ritchie Raman Maharajan Rachel Middleton Donal O’donoghue Markus Schneider 49 Florian Kronenberg 50 Barbara Bärthlein Jamie Green H. Lester Kirchner Kevin Ho 51 Angharad Marks Corri Black Gordon Prescott 52 Nick Fluck Masaaki Nakayama Mariko Miyazaki Tae Yamamoto Gen Yamada Angela Yee-Moon Wang 53 Sharon Cheung Sharon Wong Jessie Chu Henry Wu Amit Garg Eric Mcarthur Danielle Nash Varda Shalev Gabriel Chodick Peter J Blankestijn 54 Jack F.M. Wetzels 55 Arjan van Zuilen Jan a J G van den Brand 56 Lesley Inker Mark Sarnak 57 Hocine Tighiouart Haitao Zhang 58 Bénédicte Stengel 59 Marie Metzger 59 Martin Flamant 60 Pascal Houillier 61 Jean-Philippe Haymann 62 Pablo Rios 63 Nelson Mazzuchi Liliana Gadola Verónica Lamadrid Laura Solá 64 John Collins C. Raina Elley Timothy Kenealy Olivier Moranne 65 Cécile Couchoud 66 Cécile Vigneau 30, 67 Nigel Brunskill Rupert Major David Shepherd James Medcalf Csaba Kovesdy Kamyar Kalantar-Zadeh 68 Keiichi Sumida Praveen Potukuchi Hiddo J.L. Heerspink Dick de Zeeuw Barry Brenner Juan Jesus Carrero 69 Alessandro Gasparini Abdul Rashid Qureshi Carl-Gustaf Elinder Frank L.J. Visseren Yolanda van Der Graaf 70 Marie Evans Maria Stendahl Staffan Schön Mårten Segelmark 71 Karl-Göran Prütz David Naimark Navdeep Tangri Patrick Mark Jamie Traynor Colin Geddes Peter Thomson Alex Chang Ron T Gansevoort 72 Anna Köttgen Andrew Levey Luxia Zhang 73 Shoshana Ballew Jingsha Chen Josef Coresh Morgan Grams Lucia Kwak Kunihiro Matsushita Yingying Sang Aditya Surapaneni Mark Woodward 74 Kai-Uwe Eckardt 75 Brenda Hemmelgarn David Wheeler 76 Wolfgang Winkelmayer John Davis Danielle Green Michael Cheung Tanya Green Melissa Mcmahan Miklos Z. Molnar 
12 INSERM U955, équipe 21
Service de néphrologie et transplantation, IMRB - Institut Mondor de Recherche Biomédicale
Abstract : First-line therapy of minimal change nephrotic syndrome (MCNS) in adults is extrapolated largely from pediatric studies and consists of high-dose oral corticosteroids. We assessed whether a low corticosteroid dose combined with mycophenolate sodium was superior to a standard oral corticosteroid regimen. We enrolled 116 adults with MCNS in an open-label randomized controlled trial involving 32 French centers. Participants randomly assigned to the test group (n=58) received low-dose prednisone (0.5 mg/kg/day, maximum 40 mg/day) plus enteric-coated mycophenolate sodium 720 mg twice daily for 24 weeks; those who did not achieve complete remission after week 8 were eligible for a second-line regimen (increase in the prednisone dose to 1 mg/kg/day with or without Cyclosporine). Participants randomly assigned to the control group (n=58) received conventional high-dose prednisone (1 mg/kg/day, maximum 80 mg/day) for 24 weeks. The primary endpoint of complete remission after four weeks of treatment was ascertained in 109 participants, with no significant difference between the test and control groups. Secondary outcomes, including remission after 8 and 24 weeks of treatment, did not differ between the two groups. During 52 weeks of follow-up, MCNS relapsed in 15 participants (23.1%) who had achieved the primary outcome. Median time to relapse was similar in the test and control groups (7.1 and 5.1 months, respectively), as was the incidence of serious adverse events. Five participants died from hemorrhage (n=2) or septic shock (n=3), including 2 participants in the test group and 3 in the control group. Thus, in adult patients, treatment with low-dose prednisone plus enteric-coated mycophenolate sodium was not superior to a standard high-dose prednisone regimen to induce complete remission of MCNS.
Document type :
Journal articles
Complete list of metadata

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02445392
Contributor : Cécile Vigneau Connect in order to contact the contributor
Submitted on : Monday, January 20, 2020 - 10:49:26 AM
Last modification on : Thursday, October 20, 2022 - 3:10:07 PM

Links full text

Identifiers

Citation

Philippe Remy, Vincent Audard, Pierre André Natella, Gaëlle Pelle, Bertrand Dussol, et al.. Grams ME, Sang Y, Ballew SH, et al, for the Chronic Kidney Disease Prognosis Consortium. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93:1442–1451. Kidney International, 2018, 94 (5), pp.1025-1026. ⟨10.1016/j.kint.2018.08.009⟩. ⟨hal-02445392⟩

Share

Metrics

Record views

224